- Home
- RC vs DNTH Comparison
RC vs DNTH Comparison
Compare RC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- DNTH
- Stock Information
- Founded
- RC 2007
- DNTH 2015
- Country
- RC United States
- DNTH United States
- Employees
- RC N/A
- DNTH N/A
- Industry
- RC Real Estate Investment Trusts
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- RC Real Estate
- DNTH Health Care
- Exchange
- RC Nasdaq
- DNTH Nasdaq
- Market Cap
- RC 755.3M
- DNTH 651.8M
- IPO Year
- RC N/A
- DNTH N/A
- Fundamental
- Price
- RC $3.72
- DNTH $23.65
- Analyst Decision
- RC Hold
- DNTH Strong Buy
- Analyst Count
- RC 6
- DNTH 8
- Target Price
- RC $6.54
- DNTH $54.00
- AVG Volume (30 Days)
- RC 1.9M
- DNTH 342.0K
- Earning Date
- RC 08-07-2025
- DNTH 08-07-2025
- Dividend Yield
- RC 13.48%
- DNTH N/A
- EPS Growth
- RC N/A
- DNTH N/A
- EPS
- RC N/A
- DNTH N/A
- Revenue
- RC N/A
- DNTH $4,854,000.00
- Revenue This Year
- RC N/A
- DNTH N/A
- Revenue Next Year
- RC $50.48
- DNTH N/A
- P/E Ratio
- RC N/A
- DNTH N/A
- Revenue Growth
- RC N/A
- DNTH 17.87
- 52 Week Low
- RC $3.71
- DNTH $13.37
- 52 Week High
- RC $8.64
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- RC 32.26
- DNTH 67.08
- Support Level
- RC $3.80
- DNTH $19.84
- Resistance Level
- RC $3.90
- DNTH $21.18
- Average True Range (ATR)
- RC 0.13
- DNTH 1.53
- MACD
- RC -0.02
- DNTH 0.32
- Stochastic Oscillator
- RC 2.63
- DNTH 89.41
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.